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Background: Breast cancer is a heterogeneous disease displaying distinct molecular features and clinical outcome.
The molecular profile of triple-negative breast cancers (TNBCs) overlaps with that of basal-like breast cancers that
in turn show similarities with high-grade serous ovarian and endometrial carcinoma. L1CAM is an established
biomarker for the latter cancers and we showed before that approximately 18% of primary breast cancers are
positive for L1CAM and have a bad prognosis. Here we analysed the expression of L1CAM breast cancer subtypes.
Methods: We analyzed mRNA and protein expression data from different breast cancer cohorts for L1CAM,
estrogen receptor, progesterone receptor, Her-2 and Androgen receptor (AR) and correlated the data. We
performed Western blot analysis on tumor cell lysates and carried out chromatin-immuno-precipitation (CHIP)
after AR overexpression.
Results: We find that L1CAM is expressed preferentially though not exclusively in TNBCs. Using the human cancer
genome atlas database and two independent breast cancer cohorts we find that L1CAM is inversely correlated with
androgen receptor (AR) expression. We found that L1CAMhighARlow primary breast tumors have the worst clinical
outcome. Overexpression of AR in MDA-MB436 breast cancer cells decreased L1CAM expression at the protein and
mRNA level and CHIP-analysis revealed binding of AR to the L1CAM promoter region.
Conclusions: These results suggest that L1CAM in breast cancer is under AR control. The data also strongly
advocate the use of L1CAM assessment in breast cancer diagnosis. We suggest that L1CAM expression could be
causally related to the bad prognosis of TNBCs.
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Breast cancer represents a heterogeneous disease with
many distinct molecular features. In clinical practice the
classification according to estrogen receptor (ER), proges-
terone receptor (PR) or the EGF receptor family member
Her-2 is prominent as these markers influence therapeutic
options. Triple-negative breast cancers (TNBCs) lack all of
these markers and are an aggressive subtype with high rates
of proliferation and poor prognosis [1,2]. In recent years,* Correspondence: p.altevogt@dkfz.de
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unless otherwise stated.novel classifications based on the transcriptome analysis of
breast cancer tissues have been established that revealed
subtypes with distinct gene expression signatures and clin-
ical outcome [3,4]. Several intrinsic breast cancer subtypes
were established with luminal A, Luminal B, Her-2-
enriched, and basal-like (BLBC) being major groups. Recent
studies have further expanded this classification [5]. The
majority of TNBCs are of the BLBC subtype, i.e. often carry
p53 mutations and express cytokeratin 5/6 or EGFR [6].
But these characteristics are occasionally also found in ER+
or Her-2+ breast cancers [6,7].
Beside the hormone receptors ER and PR, more than
70% of primary breast cancers express the androgentral. This is an Open Access article distributed under the terms of the Creative
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expression status is a prognostic marker in non-basal
TNBCs [11] and that expression of AR is associated with
better OS and DSF irrespective of co-expression of ER
[10]. The loss of AR expression was also shown to pre-
dict early recurrence in TNBCs and BLBCs [12]. Re-
cently, Santagata et al have shown that the combined
analysis of AR, vitamin D receptor, ER and PR can im-
prove the outcome prediction [13]. Other studies have
used a 5–marker immunohistochemical panel compris-
ing ER, PR, Her-2, EGFR and Ck5/6 to identify a basal-
like subgroup within TNBCs [14]. Using gene expression
profiling Lehmann et al. have defined 6 TNBC subtypes
and identified cell lines that can serve as models for
these subtypes [15]. Thus, novel markers could lead to
better classification schemes associated with patient sur-
vival differences and offer novel insights for the treat-
ment breast tumors [13].
L1CAM, a transmembrane cell adhesion molecule of
the Ig superfamily, plays an important role in the de-
velopment of the nervous system and in the malig-
nancy of human tumors [16]. L1CAM is overexpressed
in many human carcinomas and augments cell motil-
ity, invasion and metastasis formation [17]. Several
studies have shown that L1CAM positive carcinomas
have a bad prognosis [16,18]. For gynecological cancers
we reported before that type II tumors, representing
the most aggressive serous and clear-cell endometrial
and ovarian carcinoma, are positive for L1CAM
[19-21]. In addition, a recent study has shown that the
less aggressive endometrioid EC (type I tumors) can
sometimes express L1CAM conferring a bad prognosis
to those patients [22]. Thus, L1CAM is a novel bio-
marker for the prognosis of serous ovarian and endo-
metrial cancers.
We reported before that L1CAM is also expressed in
appr. 18% of primary breast cancers [23]. However, in
this study we did not analyse particular subtypes for
L1CAM. Given the recent findings about the molecular
similarities between high-grade serous ovarian, endomet-
rial cancers and certain forms of breast cancer [5,24] we
re-investigated L1CAM in breast cancer in more detail.
In the present study we report that L1CAM is expressed
in TNBCs and is inversely correlated with the expression
of AR. Our results warrant the use of L1CAM staining
for the improved diagnosis of primary breast cancer and
suggest a link between L1CAM expression and the gen-
eral bad prognosis of TNBCs.
Methods
Patients
The study was performed in accordance with the princi-
ples of the Helsinki declaration after approval by the
local ethics committee (University of Innsbruck, Austria;University of Hamburg). Histological typing was evaluated
on H&E stained sections according to the criteria of the
WHO. Written informed consent was obtained from all
patients for use of the resected samples. Two cohorts of
primary breast cancer were analysed: 1) The Hamburg
cohort of 219 patients in which the L1CAM expression
was initially analysed [23] was re-investigated for AR
expression. 2) A second cohort of 60 patients with inva-
sive ductal carcinoma was recruited from Innsbruck
University hospital. All were of the TNBC subtype. The
clinical and histopathological data of both patient cohorts
are summarized in Table 1.
Antibodies
The mAb to the ectodomain of L1CAM (L1-14.10) was
previously described [25]. Antibodies to AR (SP107,
Ventana 760-4605), ER (Novocastra, NCL-L-ER-6F11,
ERα specific) and PR (Zymed, PR-2C5) were used for IHC.
Immunohistochemical staining and evaluation of
expression
IHC staining was performed as described in detail re-
cently [26]. Briefly, 3-4 μm thick histological paraffin
sections were cut and mounted on Superfrost Plus slides
that were exposed in a pressure cooker to EDTA pH 8.0
buffer for antigen retrieval. An automated immunohisto-
chemistry procedure was performed using the I6000
(Biogenics, San Ramos, CA) immunostainer. Endogen-
ous peroxidase activity was blocked by a 10 min treat-
ment with 3% H2O2 in methanol. Slides were incubated
with primary antibodies for 45 min and immunoperoxi-
dase staining was accomplished using the Supersensitive
detection kit with AEC or DAB (Zymed) as the substrates.
Counterstaining was performed using hematoxilin prior to
coverslipping and viewing by light microscopy. Omission
of the primary antibody was used as a negative control.
Positive AR expression was defined as >/=10 % nuclear
staining.
Biochemical analysis
SDS-PAGE under non-reducing conditions and transfer
of proteins to an Immobilon membrane using semi-dry
blotting has been described [27]. After blocking with 5%
skim milk in TBS, the blots were developed with the
respective primary antibody followed by peroxidase
conjugated secondary antibody and ECL (Perkin Elmer,
Rodgau, Germany) detection.
Transient transfection and CHIP analysis
Transient transfection of MDA-MB 436 cells was done
using jetPEI (Polyplus, Illkirch, F). 1 × 105 cells were
seeded 24 h before transfection in 6-well plates. The AR-
GFP plasmid (Plasmid 28235: pEGFP-C1-AR) was ob-
tained from Addgene [28]. The transfections were done as
Table 1 Clinical and histopathological characteristics of






Total number of cases 219 60
Patient data available 198 53
Date of surgery: 1990 - 2003 2001 - 2010
Age:
Mean (year) 56.8 58.7
Median (year) 56.6 58.5

































Table 1 Clinical and histopathological characteristics of















Died of disease 56 8
1based on routine immunohistochemical ER/PR staining.
2based on mRNA data using the cut-off values as described [23].
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lected for analysis after 48 hr. For ChIP assays, cells were
seeded in 175 cm2 dishes, transfected either with pcDNA3
control or AR plasmid, respectively. Cells were harvested
72 h after transfection. CHIP analysis with mAb to AR
was done exactly as described by the manufacturer (Active
Motif). Primers for the RT-PCR analysis of AR binding
sites in the L1CAM promoter were designed and synthe-
sized by MWG Eurofines (Ebersberg, Germany). ChIP pri-
mer pair PP1: forward: ACCTTCCTCCTCCTTCTAGGC;
reverse: GAGCGGTGGAAGACAGACAAA. ChIP primer
pair PP2: forward: AACAAGGCTTTCCTCTGGCT; re-
verse: ACAGGGCACATGAAAGGGTC.
Quantitative RT- PCR
Total RNA was isolated using the Qiagen RNeasy mini kit
(Qiagen Hilden, Germany). Reverse transcription into
cDNA was performed using RevertAid First Strand cDNA
Synthesis Kits (Fermentas, St. Leon-Rot, Germany). For
qPCR the cDNA was purified on Microspin G-50 columns
(GE Healthcare, München, Germany) and quantified
by NanoDrop spectrophotometer (ND-1000, Kisker-
Biotechnology, Steinfurt, Germany). Primers for qPCR
were designed with the DNA Star Program and were
produced by MWG Eurofines (Ebersberg, Germany).
ß-actin was used as an internal standard. The PCR reac-
tion was performed with the SYBRgreen mastermix
(Applied Biosystems, Darmstadt, Germany). The se-
quence of primers used were as following: L1CAM pri-
mer pair, forward: GACTACGAGATCCACTTGTTTA


































































































































Figure 1 L1CAM mRNA expression in the TCGA breast cancer collective negatively correlates to AR protein and mRNA expression.
Analysis of data from the Breast Invasive Carcinoma (TCGA, Provisional) study using cBioportal. The dataset includes 1002 cases of breast cancer
patients. All correlation values were calculated by spearman. (A) Differences in ERBB2, PGR, AR and PGR protein expression of samples that
express high amounts of L1CAM mRNA (L1CAM high: Expression > 1.3) to unaltered samples (L1CAM low: Expression < 1.3). (B) L1CAM mRNA
expression of specimens that express low (AR low, n = 536) or high (AR high, n = 356) amounts of AR mRNA. P < 0.0001, 95% CI = 0.06-0.11.
(C) Scatter plot of L1CAM mRNA expression to AR mRNA expression. Values are given in (RNA Seq V2 RSEM) in log2. n = 892, r = -0.34, P < 0.0001.
(D) Kaplan Meier analysis of month survival of cases that express high amounts of L1CAM (Expression > 1.3) together with low amounts of AR
(Expression < 1.3) (red line) compared to not altered patients (blue line). P = 0.018, HR = 2.38, 95% CI = 1.16-4.86. (E) Cases set showing
overexpression of L1CAM (5%, Expression > 1.3) or AR (5%, Expression > 1.3). Red boxes represent cases with expression > 1.3; gray boxes:
unaltered or < 1.3.
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primer pair, forward: GGACTTCGAGCAAGAGATGG;
reverse: AGCACTGTGTTGGCGTACAG. AR primer
pair, forward: ACAGGAGGAAGGAGAGGCTT; re-
verse: ACTACACCTGGCTCAATGGC.
FACS analysis
The staining of cells with mAbs to L1CAM and PE-
conjugated secondary antibodies has been described
[27]. Stained cells were analysed with a FACS Canto IIusing FlowJo software (Becton & Dickinson, Heidelberg,
Germany).
Statistical analysis
P-values were calculated by an unpaired t-test and 95%
confidential intervals (CI) were calculated with the
Graph Prism program. Survival curves were plotted by
Kaplan-Meier analysis and Log-Rank tests using the
SPSS.21 program. Cox regression models were cal-




































































































Figure 2 L1CAM expression is preferentially observed in TNBCs. (A) TNBCs (n = 28) and non-TNBCs (n = 438) from the TCGA breast cancer
cohort were analyzed for the expression of L1CAM. P < 0.0001, 95% CI = 0.47-1.32 (B) TNBCs (n = 28) and non-TNBCs (n = 438) from the TCGA
breast cancer cohort were analyzed for the expression of AR. P < 0.0001, 95% CI = -2.74- -1.94 (C) Distribution of histological subtypes in TNBC
and non-TNBC tumors that express L1CAM.
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were regarded as statistically significan.
Results
L1CAM and AR are negatively correlated in the TCGA
breast cancer database
We analysed the TCGA collective Breast Invasive
Carcinoma (TCGA, Provisional) with the cBioportal tool
(www.cbioportal.org). The database includes 1002 cases
of primary breast cancer patients and has protein and
mRNA expression data. Analyzing the mRNA data for
L1CAM expression, we observed high expression in 5%
(n = 50) of the cases. Next, we analyzed the positive andnegative groups for differential protein expression of ER,
PR, ERBB2 and AR. There was an inverse correlation
with protein expression of ER (P = 0.0003), PR (P =
0.000004) but not ERBB2 (P = 0.731) in agreement with
our previous work [23]. Importantly, we also observed a
highly significant inverse correlation with the expression
of AR (P = 0.00002) (Figure 1A).
We next divided the TCGA mRNA data into ARlow (n =
536) or ARhigh (n = 356) groups and carried out expression
analysis. L1CAM was significantly more abundant in the
ARlow (P < 0.0001) than in the ARhigh group (Figure 1B,C).
Kaplan-Meier curves showed a decreased survival of
L1CAM positive breast cancer patients (Figure 1D). The
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Figure 3 L1CAM mRNA expression correlates negatively to AR
expression in the Hamburg cohort. (A) Scatter plot of L1CAM
mRNA expression to AR mRNA expression. Values are given in (RNA Seq
V2 RSEM) in log2. n = 219, r = -0.294, P < 0.0001. Kaplan Meier analysis of
disease free survival (B) (AR pos, L1CAM neg vs. AR neg L1CAM pos:
P = 0.005) and overall survival (C) (AR pos, L1CAM neg vs. AR neg
L1CAM pos: P < 0.001) of cases that express different combination of
L1CAM and AR. L1CAMlow/ARhigh (blue line), L1CAMlow/ARlow (green
line), L1CAMhigh/ARhigh (red line), L1CAMhigh/AR low (violet line).
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served in individual cases of the probe-set (Figure 1E).
L1CAM expression occurs predominantly in TNBCs and
BLBCs
Next the TCGA mRNA data set was stratified into
TNBCs and non-TNBCs. L1CAM mRNA was increased
in TNBCs versus non-TNBCs. (Figure 2A). Importantly,
AR expression was decreased in TNBCs (Figure 2B) as
was recently reported by others [11]. L1CAM was also
enriched in BLBCs (Figure 2C).
L1CAM and AR expression in independent breast cancer
cohorts
L1CAM was analysed before in a primary breast cancer
cohort (Hamburg cohort) by mRNA expression profiling
[23] (see Table 1 for clinical data). We re-analyzed the in-
dependent data set for AR expression and found a strong
tendency of mutually exclusive expression between
L1CAM and AR (p < 0.0001) (Figure 3A). In this cohort
the inverse relation between L1CAM and ER (p =
0.043645), or PR (p = 0.020864) did reach statistical signifi-
cance. Although the total numbers of TNBC and HER2-
enriched tumors in the Hamburg cohort were low, the
low AR expression in TNBC could be corroborated.
L1CAM expression was high not only in TNBC, but also
in HER2-positive tumors (Additional file 1: Table S1) that
is in accordance with previous findings [23].
When the data from the Hamburg cohort were grouped
according to AR and L1CAM expression, the Kaplan-
Meier survival analysis revealed that L1CAMhighARlow tu-
mors had the worst prognosis whereas L1CAMlowARhigh
had the best prognosis in DFS and OS (Figure 3B,C). This
prognostic value retained its statistical significance in
multivariate Cox regression analysis including the classical
prognostic markers (FIGO stage, histological grading,
lymph node involvement) showing that the L1CAM/AR
status is an independent prognostic indicator for both OS
and DFS (Additional file 2: Table S2).
For validation we examined sections from a second group
of patients (Innsbruck cohort). We investigated the expres-
sion of AR and L1CAM in 60 TNBCs by IHC, of which 52
cases could be evaluated for both proteins. The clinical data
are summerized in Table 1. L1CAM expression was noticed
Case #1 Case #2 Case  #3
L1CAM
AR
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 L1CAM pos AR pos 
 3.8% (n=2) 
 L1CAM neg AR pos 
36.5% (n=19)
 L1CAM pos AR neg 
25.0% (n=13)





























AR pos, L1CAM neg 
vs. 
not altered
AR pos, L1CAM neg 
vs.
not altered
Figure 4 Staining examples for L1CAM and AR breast cancer tissue sections. (A) Staining pattern, showing the number of cases of the
TNBC Innsbruck cohort that were stained by IHC for L1CAM and AR. Details are summarized in Table 1 (n = 52). (B) IHC staining for L1CAM and
AR on representative sections from the Innsbruck cohort. Kaplan Meier analysis of disease free survival (DFS) (C) and overall survival (OS) (D) of
the Innsbruck cohort that were stained by IHC for L1CAM and AR.
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sults presented above, the L1CAM positive TNBCs were
nearly exclusively negative for AR (13/15). But in most
of the cases we detected AR specific staining in adjacent
normal tissues or in L1CAM negative TNBC tumors.
Examples for typical L1CAM and AR stainings are
shown in Figure 4B.
When analyzing the Innsbruck cohort by Kaplan-
Meier, we found that tumors that were positive forL1CAM or negative for AR had a unfavorable prog-
nosis in DFS and OS (Figure 4C,D). These differences
did not reach statistical significance most likely due
to short follow-up and low sample numbers. Interest-
ingly, the combined staining of AR and L1CAM,
showed that AR positive/L1CAM negative tumors
had the best prognosis for DFS (P = 0.031; HR: 4.57)
and OS (P = 0.043; HR: 4.63) when compared to the
rest (Figure 4C,D).












































































































































































Figure 5 (See legend on next page.)
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Figure 5 Analysis of breast cancer cell lines for L1CAM and AR expression. (A) The TCGA Cancer Cell Line Encyclopedia (Novartis/Broad,
Nature 2012) of breast cancer cell lines was analyzed with the cBio data portal. The dataset includes 59 different breast cancer cell lines. Scatter
plot showing L1CAM mRNA expression to AR mRNA expression. Values are given in mRNA Expression z-Scores. r = -0.51, P < 0.0001. (B) Western
blot analysis of breast cancer cell lines: MDA361, MDA415, MDA436, HDQP1, BT20 and MCF7. Blot was analyzed with specific antibodies against
AR, L1CAM and GAPDH as a loading control. (C) Representative FACS analysis of MDA436 cells that were transfected with an AR-EGFP vector or
Mock. Upper row: FACS curves (% cells against log2 intensity) of EGFP and L1CAM (L1CAM-APC) stained with APC. Lower row: calculated mean
fluorescence of each curve (n = 4). Transfected cells of (C) were analyzed by qPCR for AR (D) and L1CAM (E) expression. (F) Western blot analysis
of MDA436 cells that were transfected with AR-EGFP, an empty vector or mock. Blots were analyzed with specific antibodies against AR, L1CAM
and GAPDH as loading control (n = 3).
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We next tried to confirm the inverse correlation of
L1CAM and AR in in breast cancer cell lines. We
analysed TCGA expression data from 59 breast can-
cer cell lines [5] (www.cbioportal.org). Dot plot ana-
lysis of L1CAM mRNA expression versus AR gave a
z-score r = -0.51, (P < 0.0001) (Figure 5A). These data
confirmed that AR expression is inversely correlated
to L1CAM in primary tumor tissues and in breast
cancer cell lines.
We selected 6 cell lines with low or high AR expression
and carried out biochemical analysis. Indeed, ARhigh cells
(MDA-MB361, MDA-MB415) expressed no L1CAM as
detected by Western blot analysis (Figure 5B). In contrast,
ARlow expressing cells (MDA-MB436, HDQP1, BT20)
expressed high levels of L1CAM (Figure 5B). MCF-7 cells
expressed AR and low levels of L1CAM (Figure 5B).
Overexpression of AR leads to L1CAM down-regulation
For further analysis we selected MDA-MB436 cells be-
cause of its low levels of AR expression. We transiently
over-expressed AR and FACS analysis of GFP expression
showed appr. 20% transfected cells after 48 hr (Figure 5C)
and RT-PCR analysis confirmed strong expression of AR
(Figure 5D). Importantly, L1CAM expression was de-
creased (Figure 5E). Staining of the transfected cells for
L1CAM revealed a clear reduction at the cell surface
(Figure 5C). These results were confirmed by WB ana-
lysis of total L1CAM (Figure 5F).
CHIP analysis shows binding of AR to the L1CAM
promoter
AR is a transcription factor and we reasoned that it might
regulate L1CAM expression by binding to the L1CAM
promoter. We examined the structure of the L1CAM
promoter for putative AR binding sites. As indicated in
Figure 6A, the DNA sequence analysis predicted three
binding sites between exon 0 and exon 1 which is part of
the L1CAM “promoter 2” region [29]. To demonstrate the
binding of AR to this promoter region, we carried out
Chromatin-IP analysis. MDA-MB436 cells were trans-
fected with the AR-GFP plasmid and Chromatin-IP was
carried out using anti-AR specific mAb. To analyze the
binding of AR to the predicted binding sites, theprecipitated chromatin-DNA was analyzed using qRT-PCR
with primers specific for the selected regions. The over-
expression of AR led to a strong binding to the identified
binding sites BS1, 2 and BS3 as detected by RT-PCR
(Figure 6B,C). Agarose gel analysis showed that both
products had the expected size of 170 or 247 bp, re-
spectively (Figure 6D,E). For specificity control we con-
firmed that all immuno-precipitated DNAs showed no
products with off-target control primers (not shown) and
no precipitates with irrelevant control IgG (Figure 6B-E).
These controls suggested that AR binding sites in the
L1CAM promoter were specifically occupied after over-
expression. Finally, AR over-expression led to binding to
the promoter of CAMKK a known target gene of AR [30]
(Figure 6F).
Discussion
L1CAM expression has been found in gynecological
carcinomas such as ovarian and endometrial cancers
[19-21] but was also reported to be present in a low
percentage of breast carcinomas [23]. Here we have an-
alyzed more closely the distribution of L1CAM expres-
sion in breast cancer. We found that i) L1CAM is
preferentially but not exclusively expressed in TNBCs;
ii) L1CAM expression is inversely correlated with the
expression of AR in three independent breast cancer
cohorts; iii) L1CAM and AR are inversely correlated in
breast cancer cell lines and over-expression of AR
down-regulates L1CAM expression in MDA-MB436
cells; iv) upon over-expression AR binds to AR re-
sponse elements in the L1CAM promoter as revealed
by CHIP-analysis. These findings suggest that AR can
directly control L1CAM expression in breast cancer
and adds a new facet to the complex regulation of
L1CAM in cancer.
In previous work we and others have studied the role
of L1CAM in cell motility, invasion, chemoresistance
and metastasis formation (for review see [17,18]). For
MDA-MB231 breast cancer cells we showed, that the
over-expression of L1CAM or its up-regulation by the
EMT-inducer TGF-β augmented matrigel invasion and
migration on ECM components [31]. This was associ-
ated with activation of the NFkB signalling pathway [31].
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Figure 6 (See legend on next page.)
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Figure 6 AR binds to sites located between Exon 0 and Exon 1 of the L1CAM gene. (A), Schematic representation of the localization of the
AR binding sites in the L1CAM gene. Upper row: Distal localization of the AR binding sites in relation to the L1CAM promoter region. Middle row:
localization of binding sites 1 and 2 (BS 1+2) and binding site 3 (BS 3) between Exon 0 and Exon 1. Lower row: The localizations of primer
products PP1 and PP2 are shown. An immune-precipitation (IP) of MDA436 cells transfected with AR-EGFP or mock was performed with an AR
(AR-IP) antibody or a IgG (IgG-IP) control antibody. Precipitated DNA was analyzed by qPCR amplification for BS 1+2 (B) and BS 3 (C) (n = 3). The
input was used as a positive control. Agarose gel electrophoresis of the BS 1+2 (D) and BS 3 (E) amplification products. (F) Precipitated DNA was
analyzed by qPCR amplification for the AR binding site in the CAMKK gene. Note that the same AR-IP material was used but CAMKK specific
primers (n = 3).
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gression [17].
We found that L1CAM expression is more abundant
in TNBCs as compared to non-TNBCs. This was ob-
served in the TCGA cohort and was confirmed in in-
dependent patient groups. L1CAM was also found
predominantly in the BLBC group consistent with
the notion that TNBCs and BLBCs largely overlap.
However, although preferentially expressed in these
subclasses, L1CAM is occasionally also detected in
non-TNBCs, especially in HER2-positive tumors (see
Additional file 2: Table S2 and [23]).
Although it is well accepted that the expression of
hormonal receptors such as ER and PR is associated
with better outcome in women with breast cancer the
role of AR has been less well investigated despite the
fact that it is expressed in many breast cancers [8]. A
recent systematic review and meta-analysis of 7693 pa-
tients including 19 different studies has come to the
conclusion that AR expression appears to be associ-
ated with improved OS and DSF at 3 or 5 year time-
points [10]. Beside its predictive value, AR in the
absence of ER expression in TNBCs may have the po-
tential for targeted therapy using pharmacological an-
tagonists developed for the treatment of prostate
cancer [10,32,33].
Gaspari et al reported that AR is significantly down-
regulated in TNBCs but up-regulated in Her2+, ER+, PR+
cases [11]. We find that the expression of AR is inversely
correlated with L1CAM in the TCGA database and two
idependent cohort. Moreover, in the panel of 56 breast
cancer cell lines a similar observation was made.
As AR is a nuclear transcription factor we investigated
whether the loss or down-regulation of AR might promote
L1CAM expression. In line with this notion, we observed
that AR over-expression in MDA-MB436 cells suppressed
L1CAM at the mRNA and protein level. We identified
three AR binding sites in the L1CAM promoter region lo-
calized between exon 0 and 1. Using CHIP analysis we
provided suggestive evidence that AR can bind to these
sites. Thus, in breast cancer AR is a negative regulator of
L1CAM expression. In endometrial carcinoma we have
previously identified the transcription factor Slug as a
positive regulator for L1CAM [29]. In addition, in thelatter tumor L1CAM is subject to epigenetic regulation
via methylation of the L1CAM promoter [34] and by
miR34a [35]. Thus, the present finding showing that AR
can regulate L1CAM in a direct fashion adds a novel
element to the complex regulation of L1CAM in cancer.
Recent TCGA studies comparing different tumor types
showed many molecular commonalities between high-
grade serous ovarian, serous endometrial and BLBCs sug-
gesting a related aetiology [5,24]. We report here that
L1CAM is a prototype gene product that is up-regulated
in all three tumor entities and confers a bad prognosis to
the patients. It will be interesting to study whether the
stratification of these cancers based on L1CAM expres-
sion will show other commonalities presently unknown.
Conclusion
In conclusion, the present paper strongly supports the
use of L1CAM in breast cancer diagnosis and suggests a
link between L1CAM expression and the general bad
prognosis of TNBCs.
Additional files
Additional file 1: Table S1. L1CAM and AR mRNA expression in different
molecular subtypes of the Hamburg cohort.
Additional file 2: Table S2. Multivariate Cox regression analysis
including FIGO stage, histological grading, nodal involvement and
L1CAM/AR combination.
Abbreviations
AR: Androgen receptor; BLBC: Basal-like breast cancer; DFS: Disease-free survival;
EMT: Epithelial-mesenchymal transition; ER: Estrogen receptor; Her-2: Human
epidermal growth factor receptor 2; IHC: Immunhistochemistry; L1CAM: L1 cell
adhesion molecule; mAb: Monoclonal antibody; OS: Overall survival;
PR: Progesterone receptor; RFS: Recurrence free survival; TNBC: Triple-negative
breast cancer; qRT-PCR: Quantitative real-time PCR; CI: Confidence interval;
HR: Hazard ratio.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KD carried out the molecular studies, made the figures and drafted the
manuscript. PA and MF wrote the manuscript and designed the study. KML
and IW collected and analyzed the Hamburg cohorts. MH, EMH, SR and AGZ
collected and analyzed the Innsbruck cohorts. AH, ABA and MF carried out
and analyzed the IHC. US analyzed the L1CAM promoter region and NPB
helped designing the concept and the figures. All authors read and
approved the final manuscript.
Doberstein et al. BMC Cancer 2014, 14:958 Page 12 of 13
http://www.biomedcentral.com/1471-2407/14/958Acknowledgements
We thank Natalie Erbe-Hofmann for skillful technical assistance. This work
was supported by EC grant OVCAD to MF, PA and AGZ.
Author details
1Tumor Immunology Programme, D015, German Cancer Research Center,
Heidelberg, Germany. 2Department of Gynecology, University Medical Center
Hamburg-Eppendorf, Hamburg, Germany. 3Chemical Laboratories, Kaplan
Medical Center, Rehovot, Israel. 4Department of Gynecology, Kaplan Medical
Center, Rehovot, Israel. 5Department of Gynecology and Obstetrics, Medical
University of Innsbruck, 6020 Innsbruck, Austria. 6Institute of Pathology,
Medical University of Innsbruck, 6020 Innsbruck, Austria.
Received: 8 September 2014 Accepted: 11 December 2014
Published: 15 December 2014
References
1. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA,
Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical
features and patterns of recurrence. Clin Cancer Res 2007,
13(15 Pt 1):4429–4434.
2. Oakman C, Viale G, Di Leo A: Management of triple negative breast
cancer. Breast 2010, 19(5):312–321.
3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C,
Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular
portraits of human breast tumours. Nature 2000, 406(6797):747–752.
4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB,
van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D,
Lonning PE, Borresen-Dale AL: Gene expression patterns of breast
carcinomas distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci U S A 2001, 98(19):10869–10874.
5. Cancer Genome Atlas N: Comprehensive molecular portraits of human
breast tumours. Nature 2012, 490(7418):61–70.
6. Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, Holmberg
LH, Tutt AN, Pinder SE: Comparison of basal-like triple-negative breast
cancer defined by morphology, immunohistochemistry and
transcriptional profiles. Mod Pathol 2013, 26(7):955–966.
7. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara
S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC,
Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS: Basal-like and triple-negative
breast cancers: a critical review with an emphasis on the implications for
pathologists and oncologists. Mod Pathol 2011, 24(2):157–167.
8. Kotsopoulos J, Narod SA: Androgens and breast cancer. Steroids 2012, 77(1–2):1–9.
9. Chang C, Lee SO, Yeh S, Chang TM: Androgen receptor (AR) differential
roles in hormone-related tumors including prostate, bladder, kidney,
lung, breast and liver. Oncogene 2014, 33(25):3225-3234.
10. Vera-Badillo FE, Templeton AJ, de Gouveia P, Diaz-Padilla I, Bedard PL,
Al-Mubarak M, Seruga B, Tannock IF, Ocana A, Amir E: Androgen receptor
expression and outcomes in early breast cancer: a systematic review and
meta-analysis. J Natl Cancer Inst 2014, 106(1):djt319.
11. Gasparini P, Fassan M, Cascione L, Guler G, Balci S, Irkkan C, Paisie C, Lovat F,
Morrison C, Zhang J, Scarpa A, Croce CM, Shapiro CL, Huebner K: Androgen
receptor status is a prognostic marker in non-Basal triple negative breast
cancers and determines novel therapeutic options. PLoS ONE 2014, 9(2):e88525.
12. Thike AA, Yong-Zheng Chong L, Cheok PY, Li HH, Wai-Cheong Yip G,
Huat Bay B, Tse GM, Iqbal J, Tan PH: Loss of androgen receptor expression
predicts early recurrence in triple-negative and basal-like breast cancer.
Mod Pathol 2014, 27(3):352–360.
13. Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, Harrell JC, McNamara
G, Schwede M, Culhane AC, Kindelberger D, Rodig S, Richardson A, Schnitt SJ,
Tamimi RM, Ince TA: Taxonomy of breast cancer based on normal cell
phenotype predicts outcome. J Clin Investig 2014, 124(2):859–870.
14. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM,
Nielsen TO: Basal-like breast cancer defined by five biomarkers has
superior prognostic value than triple-negative phenotype. Clin Cancer Res
2008, 14(5):1368–1376.
15. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y,
Pietenpol JA: Identification of human triple-negative breast cancer
subtypes and preclinical models for selection of targeted therapies.
J Clin Investig 2011, 121(7):2750–2767.16. Schafer MK, Altevogt P: L1CAM malfunction in the nervous system and
human carcinomas. Cell Mol Life Sci 2010, 67(14):2425–2437.
17. Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, Altevogt P:
L1CAM: a major driver for tumor cell invasion and motility. Cell Adhes
Migr 2012, 6(4):374–384.
18. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze’ev A: L1-CAM in cancerous
tissues. Expert Opin Biol Ther 2008, 8(11):1749–1757.
19. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A,
Edler L, Ben-Arie A, Huszar M, Altevogt P: L1 expression as a predictor of
progression and survival in patients with uterine and ovarian
carcinomas. Lancet 2003, 362(9387):869–875.
20. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, Edler L,
Munch M, Muller-Holzner E, Jerabek-Klestil S, Abdel-Azim S, Marth C, Zeimet
AG, Altevogt P, Fogel M: Up-regulation of L1CAM is linked to loss of hor-
mone receptors and E-cadherin in aggressive
subtypes of endometrial carcinomas. J Pathol 2010, 220(5):551–561.
21. Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E,
Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M,
Altevogt P: Prognostic significance of L1CAM in ovarian cancer and its role
in constitutive NF-kappaB activation. Ann Oncol 2012, 23(7):1795–1802.
22. Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA,
Muller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP,
Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A,
Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer
M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M: L1CAM in early-stage
type I endometrial cancer: results of a large multicenter evaluation.
J Natl Cancer Inst 2013, 105(15):1142–1150.
23. Schroder C, Schumacher U, Fogel M, Feuerhake F, Muller V, Wirtz RM, Altevogt
P, Krenkel S, Janicke F, Milde-Langosch K: Expression and prognostic value of
L1-CAM in breast cancer. Oncol Rep 2009, 22(5):1109–1117.
24. Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD,
Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C,
Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA:
Integrated genomic characterization of endometrial carcinoma.
Nature 2013, 497(7447):67–73.
25. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M:
Expression profile analysis in multiple human tumors identifies L1
(CD171) as a molecular marker for differential diagnosis and targeted
therapy. Hum Pathol 2006, 37(8):1000–1008.
26. Fogel M, Harari A, Muller-Holzner E, Zeimet AG, Moldenhauer G, Altevogt P:
A standardized staining protocol for L1CAM on formalin-fixed, paraffin-
embedded tissues using automated platforms. Int J Biol Markers 2014,
29(2):e180–e183.
27. Gutwein P, Oleszewski M, Mechtersheimer S, Agmon-Levin N, Krauss K,
Altevogt P: Role of Src kinases in the ADAM-mediated release of L1
adhesion molecule from human tumor cells. J Biol Chem 2000,
275(20):15490–15497.
28. Tilley WD, Marcelli M, Wilson JD, McPhaul MJ: Characterization and
expression of a cDNA encoding the human androgen receptor. Proc Natl
Acad Sci U S A 1989, 86(1):327–331.
29. Pfeifer M, Schirmer U, Geismann C, Schafer H, Sebens S, Altevogt P: L1CAM
expression in endometrial carcinomas is regulated by usage of two
different promoter regions. BMC Mol Biol 2010, 11:64.
30. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A,
Scott H, Madhu B, Sharma N, Bon H, Zecchini V, Smith DM, Denicola GM,
Mathews N, Osborne M, Hadfield J, Macarthur S, Adryan B, Lyons SK, Brindle
KM, Griffiths J, Gleave ME, Rennie PS, Neal DE, Mills IG: The androgen
receptor fuels prostate cancer by regulating central metabolism and
biosynthesis. EMBO J 2011, 30(13):2719–2733.
31. Kiefel H, Bondong S, Pfeifer M, Schirmer U, Erbe-Hoffmann N, Schafer H,
Sebens S, Altevogt P: EMT-associated up-regulation of L1CAM provides
insights into L1CAM-mediated integrin signalling and NF-kappaB
activation. Carcinogenesis 2012, 33(10):1919–1929.
32. Shah PD, Gucalp A, Traina TA: The role of the androgen receptor in
triple-negative breast cancer. Women’s health 2013,
9(4):351–360.
33. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D’Amato NC,
Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gomez F, Medicherla S,
Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA,
Richer JK: Role of the androgen receptor in breast cancer and preclinical
analysis of Enzalutamide. Breast Cancer Res 2014, 16(1):R7.
Doberstein et al. BMC Cancer 2014, 14:958 Page 13 of 13
http://www.biomedcentral.com/1471-2407/14/95834. Schirmer U, Fiegl H, Pfeifer M, Zeimet AG, Muller-Holzner E, Bode PK, Tischler
V, Altevogt P: Epigenetic regulation of L1CAM in endometrial carcinoma:
comparison to cancer-testis (CT-X) antigens. BMC Cancer 2013, 13:156.
35. Schirmer U, Doberstein K, Rupp AK, Bretz NP, Wuttig D, Kiefel H, Breunig C,
Fiegl H, Muller-Holzner E, Zeillinger R, Schuster E, Zeimet AG, Sultmann H,
Altevogt P: Role of miR-34a as a suppressor of L1CAM in endometrial
carcinoma. Oncotarget 2014, 5(2):462–472.
doi:10.1186/1471-2407-14-958
Cite this article as: Doberstein et al.: L1CAM is expressed in triple-negative
breast cancers and is inversely correlated with Androgen receptor. BMC
Cancer 2014 14:958.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
